2025年指引假设外汇汇率截至2024年12月31日的全年有效。企业层面的指引包括当前预期的资本配置影响，包括收购、股票回购和股息。2024年Labcorp企业的收入为130.1亿美元，诊断实验室收入为101.4亿美元，生物制药实验室服务收入为29.2亿美元。2025年的收入指引包括6.7%至8.0%的增长。调整后每股收益在2024年为14.57美元，2025年指引为15.60至16.40美元。
以上内容来自Benzinga Earnings专栏，原文如下：
Guidance for 2025
The following guidance assumes foreign exchange rates effective as of December 31, 2024, for the full year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.
| (Dollars in billions, except per share data) | ||||
| Results | 2025 Guidance | |||
| 2024 | Low | High | ||
| Revenue | ||||
| Labcorp Enterprise (1)(2) | $13.01 | 6.7 % | 8.0 % | |
| Diagnostics Laboratories (3) | $10.14 | 6.5 % | 7.7 % | |
| Biopharma Laboratory Services (4) | $2.92 | 3.0 % | 5.0 % | |
| Adjusted EPS | $14.57 | $15.60 | $16.40 | |
| Free Cash Flow | $1.10 | $1.10 | $1.25 | |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.